Crossject is revolutionizing needle free injection

Colonne 1

Crossject is revolutionizing the administration of well-established, clinically-proven treatments and bringing unprecedented advantages to patients with its innovative, needle-free auto-injector ZENEO®. The prefilled, single-use device propels the medicine through the skin in less than a tenth of a second. Crossject currently has eight ZENEO® solutions in advanced stages of development, seven of which are for emergency situations.  

Zeneo illustration


Our news

Image de l'actualité

ZENEO® Midazolam earns the orphan drug designation

Résumé de l'actualité

The FDA has granted Orphan Drug designation to ZENEO® Midazolam for the treatment of status epileptics.

Image de l'actualité

ZENEO® receives the JANUS

Résumé de l'actualité

Crossject is proud to announce that ZENEO® received the 2017 JANUS Prospective award from the French Institute of Design. 


Financial news: Annual 2017 results and business update

Sommaire ou résumé

Annual 2017 results and business update